Search Results
Your search for ,USE matches 11180 pages
Showing 6701 - 6750Equivalent Response Rates With Trastuzumab or a Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer
In part 1 of the Heritage study, a phase III equivalence trial reported in JAMA, Hope S. Rugo, MD, of the University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, and colleagues found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar...
Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go
Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhood cancer is rarer by far than adult cancer. These and other phenomena in pediatric oncology were the subject of a workshop held by the Friends of...
Monoclonal Antibody Therapy With Daratumumab in Multiple Myeloma: Expanding Therapeutic Horizons
The advent of successful monoclonal antibody therapy in the treatment of relapsed/refractory myeloma has dramatically improved the prognosis of patients for whom currently approved novel therapies have failed. In 2015, the approval of the combination of elotuzumab (Empliciti) with lenalidomide...
Expert Point of View: Susan O'Brien, MD
Susan O’Brien, MD, Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center, University of California Irvine Health, put the venetoclax (Venclexta) monotherapy study in context. “The study by Jones et al is impressive. Patients who fail on a prior kinase...
Updated Data on Treatment With Ibrutinib and Venetoclax in Patients With CLL/SLL
Long-term follow-up of treatment with ibrutinib (Imbruvica) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) has shown high response rates that are durable. At 5 years, 89% of patients with treatment-naive and relapsed or...
Study Projects HIV-Related Cancer Burden to Decline
The total number of cancer cases diagnosed among people living with the human immunodeficiency virus (HIV) is projected to decline in coming years, due mostly to declines in non-Hodgkin lymphoma and Kaposi sarcoma. Certain other cancers, such as prostate and lung, are expected to rise, according to ...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
Stage I Lung Cancer: Treatment Advances Have Changed the Game
Read more in the Journal of Oncology Practice (JOP). Visit ASCOPubs.org/journal/jop Patients with stage I lung cancer are achieving excellent local tumor control, thanks to an evolution in radiotherapy and surgical approaches. Jeffrey A. Bogart, MD, Professor and Chair of the Department of...
Institute for Clinical Immuno-Oncology White Paper Highlights Challenges, Progress, and Priorities in Immunotherapy
Momentum around immunotherapies for cancer continues to build, but the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers, patients,...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Cranberry
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time....
New Study Finds Global Smoking Rates on Decline but Shows More Work Is Still Needed
On March 21, 2017, Gravely et al published a study1 in Lancet Public Health on the 2003 global tobacco control treaty’s impact on the adoption of tobacco-reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed...
Research Reveals New Treatment Possibilities for Prostate Cancer
Not all cancer research will result in a positive outcome for patients, but all research does provide information that continues to advance the treatment of cancer care. Recent clinical trials, including one funded in part by the Conquer Cancer Foundation (CCF) of ASCO, show that most prostate...
Conquer Cancer Foundation Recognizes Global Oncology Researchers With International Innovation Grant
The Conquer Cancer Foundation (CCF) of ASCO recently announced the recipients of its 2017 International Innovation Grant. The 1-year grant of up to $20,000, given directly to each awardee’s nonprofit organization or government agency, funds research projects aimed at improving cancer care in low-...
Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach, in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA).1 Together, stomach and esophageal cancers...
ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...
Can You Hear Me Now? Listening to the Cancer Patient
At this year’s ASCO Quality Care Symposium, Neeraj K. Arora, PhD, Associate Director at the Patient-Centered Outcomes Research Institute, opened his presentation by stressing that integrating the patient’s voice and experience into the clinical setting produces better health outcomes.1 Dr. Arora,...
Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
An Oncology Care Model: One Institute’s Experience
At this year’s ASCO Quality Care Symposium, Blase N. Polite, MD, MPP, Associate Professor of Medicine at The University of Chicago Medical Center, examined his practice’s experience with the Oncology Care Model, a Centers for Medicare & Medicaid Services test payment and delivery program...
FDA Permits Marketing for Digital Pathology Solution for Primary Diagnostic Use
The U.S. Food and Drug Administration (FDA) has permitted marketing of the Philips IntelliSite Pathology Solution (PIPS, Philips Medical Systems Nederland B.V.), as an aid to pathologists to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin...
Expert Point of View: Kelly M. McMasters, MD, PhD
“Several gene-expression profiles have been evaluated to predict prognosis in colorectal cancer, but none have become widely accepted or U.S. Food and Drug Administration–approved. This has important implications for deciding which patients may benefit from adjuvant chemotherapy,” commented...
Machine Learning Model Predicts Colorectal Cancer Recurrence
A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...
Deintensifiying Treatment of HPV-Positive Oropharyngeal Cancer Could Reduce Toxicity While Maintaining Function and Survival
“The status quo for HPV [human papillomavirus]-associated oropharyngeal squamous cell carcinoma is not sufficient.… Our treatment is effective, but the toxicity associated with it is not tolerable.” And HPV-associated oropharyngeal cancer “is a cancer of relatively younger patients,” said Nishant...
Next-Generation Genitourinary Oncology: Keeping One’s Powder Dry
There is a new yin-yang of management in genitourinary oncology, with the balance of opposing power focused among cancer cells, kinase inhibition, and lymphocyte function, representing a shift in the fashions of treatment somewhat away from chemotherapy. This linear progress has been complicated...
Attrition High but Positive Trends Observed in Web-Based Intervention Addressing Caregiver Burden
High attrition but positive trends such as increased “benefit finding” were observed with a Web-based intervention designed to address the psychosocial burden on informal caregivers, according to Allison J. Applebaum, PhD, a licensed clinical psychologist at Memorial Sloan Kettering Cancer Center...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice Guideline,” was published by Sher et ...
Effect of Radiotherapy Boost for Ductal Carcinoma in Situ After Whole-Breast Radiotherapy
In an analysis reported in JAMA Oncology, Moran et al found that a radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy was associated with a reduction in the risk for ipsilateral breast tumor recurrence. Study Details The analysis pooled...
FDA Removes Risk Evaluation and Mitigation Strategy Requirements for Erythropoiesis-Stimulating Agents
On April 13, the U.S. Food and Drug Administration (FDA) removed the risk evaluation and mitigation strategy (REMS) requirements for the use of epoetin alfa and darbepoetin alfa to treat patients with anemia due to associated myelosuppressive chemotherapy. The Agency's announcement regarding...
Satisfaction With Surgical Decision-Making in Women Considering Contralateral Prophylactic Mastectomy for Breast Cancer
In a study reported in JAMA Surgery, Katz et al found that most patients considering contralateral prophylactic mastectomy for stage 0 to II breast cancer were satisfied with surgical decision-making. Most surgeons discussed contralateral prophylactic mastectomy and most did not recommend against...
U.S. Preventive Services Task Force Seeks Comments on Draft Recommendation Statement on Screening for Prostate Cancer
On April 11, the U.S. Preventive Services Task Force (USPSTF) posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with...
ASCO Research Statement: Tapping the Potential of Observational Research
In a research statement reported in the Journal of Clinical Oncology by Visvanathan et al, ASCO has outlined steps for incorporating high-quality observational research into the evidence base for clinical decision-making. As stated by the authors: “ASCO believes that high-quality...
New ACS CAN Report Examines Expected Patient Costs for Common Cancer Diagnoses
On April 11, the American Cancer Society Cancer Action Network (ACS CAN) released its first report examining the costs of treating cancer, specifically the out-of-pocket portion patients face. The report, released at the organization’s annual national policy forum, found U.S. cancer patients...
Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness
A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...
Annual Report to the Nation: Cancer Death Rates Continue to Decline
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the National Cancer Institute. The report...
FDA Grants Marketing Authorization for Ipsogen JAK2 RGQ PCR Kit to Detect JAK2 Genetic Mutations
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to the ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH, to detect mutations affecting the Janus tyrosine kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating...
Thomas E. Starzl, MD, PhD, ‘Father of Modern Transplantation,’ Dies at Age 90
Scientific and clinical pioneers have one thing in common: they move beyond their comfort zone and take calculated risks. One such pioneer, whose calculated risks gave hope to otherwise hopelessly ill people, was Thomas E. Starzl, MD, PhD, who performed the world’s first successful liver...
Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
On March 13, the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) was approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast ...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on integration of palliative care into standard oncology care.1 This update of a 2012 ASCO provisional clinical opinion2 is based on an Expert Panel’s systematic review of data reported between...
Cardiac Dysfunction in Survivors of Adult Cancers
The success of cancer therapy has led us to an interesting place. Patients with cancer are certainly concerned about collateral damage that may occur with the treatment of their condition; however, impressive improvements in survival with treatment of many cancers are so compelling that these...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers.1 Recommendations were developed by an expert panel...
Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot
The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
Expert Point of View: Alessandro Volpe, MD
Formal discussant of this abstract, Alessandro Volpe, MD, of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, commented that nephron-sparing surgery is recommended for clinical stage T1 tumors; however, when compared with ablation, the advantages of...
Evolving Role for Cryoablation in Treating Small Renal Masses
Selected “healthy” patients with clinical T1 renal cell carcinoma may be safely treated with percutaneous cryoablation, according to a single-center study of experience at the Mayo Clinic.1 “In healthier patients, our experience shows that cryoablation achieved good short-term oncologic control...
New Constructs for Use in the Identification of Depression in Older Patients With Cancer
Elderly patients with cancer are far less likely to be diagnosed with depression than patients in any other age group for two primary reasons: There is an overlap between cancer symptoms/treatment side effects and the diagnostic criteria for depression, and older adults are more likely to present...
